BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Antibody Drug Conjugates

Biointron Launches RushData to Accelerate AI-Driven Antibody Discovery with High-Throughput Experimental Validation

1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design Custom workflows for ...

July 28, 2026 | News

ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...

July 27, 2026 | News

Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303

Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...

July 24, 2026 | News

Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs

Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...

July 22, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC

Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...

July 21, 2026 | News

Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit

New ready-to-use protein expression kit now available eviCHO Expression Kit simplifies transient protein expression workflows and enables faster, ...

July 17, 2026 | News

Kelun-Biotech’s Sac-TMT–Keytruda Combination Outperforms Standard First-Line Therapy in Phase III Lung Cancer Trial

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-L...

July 16, 2026 | News

Leads Biolabs' Opamtistomig Receives China's Priority Review for Advanced Neuroendocrine Cancer

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Op...

July 14, 2026 | News

WuXi Biologics' Hebei Facility Clears US FDA Pre-License Inspection for Commercial Manufacturing

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance ma...

July 13, 2026 | News

Sofinnova-Backed Myricx Bio to Join Novartis in Up to $1.5 Billion ADC Deal

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines th...

July 07, 2026 | News

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announced ...

July 03, 2026 | News

Lonza Expands Commercial ADC Payload-Linker Manufacturing at Visp to Support Growing Oncology Pipeline

Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment...

July 01, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Stay Connected